Degenerative disc disease (DDD) is a predominant contributor (~40%) to the genesis of spinal pain and is a major cause of disability worldwide, imposing enormous socio-economic burden and clinical costs to society. The 2010 Global Burden of Disease Study estimated that low back pain is among the top 10 diseases and injuries that account for the highest number of disability-adjusted life years worldwide. Approximately 25% of the population in United States of America suffers from lower back and neck pain at costs greater than $100 billion annually. Current surgical treatments including fusion and disc replacement do not attempt to slow the degenerative process or promote repair. In fact, a meta-analysis suggested that lumbar fusion might result in a higher prevalence of adjacent segment degeneration or disease than motion-preserving procedures. Thus, there is an urgent and unmet need for the development of a novel, effective therapeutic agent that can biologically repair the damaged intervertebral disc.
Using a regenerative medicine approach, Notogen has developed a therapeutic to stop and reverse spinal disc degeneration, a condition strongly associated with back pain. This novel approach has been validated in multiple animal studies and is capable of mediating degeneration of the disc in contrast to unvalidated stem cell treatments and invasive surgical interventions. The product is an injectable solution that is faster to administer, more cost-effective, and less invasive to the patient than existing treatments.
We have performed extensive cellular and molecular investigations, and a lengthy publication record leading to the development of our intervention. This unique, biological approach to the treatment of DDD may significantly address the socioeconomics of rising healthcare costs and through our regenerative medicine approach, help to address the current opioid epidemic.
Meet the team:
From left to right - Muhammad Zia Karim, Scientific Associate I, Research; Ajay Matta, Scientific Associate I, Research; Mark Erwin, Chief Science Officer, Founder; Hoda Gerami, Technician I, Research; Xiaomei Sophia Wang, Technician II, Research